PIER

The Marriott Vacation Clubs™ Announces Expanding City Collection With New Waikiki Property Now Open for Booking

Retrieved on: 
Thursday, March 28, 2024
Commercial Building & Real Estate, Vacation, Lodging, Construction & Property, Destinations, Travel, Tourist Attractions, Bryant Park, Culture, Learning, Walking, VAC, The Custom House, Marriott Vacation Club, Museum, Clock Tower, Mayflower, Ghirardelli Square, City, History, Transport, Midtown Manhattan, Balboa Park, Loyalty, PIER, Gaslamp Quarter, San Diego, Collection, Marriott Vacations Worldwide, Ocean Drive, Heart, Restaurant, San Francisco Bay Area, Multimedia, Member, Custom House, Hotel

With that in mind, today the company announces The Marriott Vacation Clubs City Collection .

Key Points: 
  • With that in mind, today the company announces The Marriott Vacation Clubs City Collection .
  • (Photo: Business Wire)
    As part of the City Collection’s growing portfolio, Marriott Vacation Club® expects to open a seven-story vacation ownership property in Waikiki later this year.
  • Each City Collection property has a City Insider on-site to help maximize an Owner’s, Member’s or guest’s experience.
  • To learn more about The Marriott Vacation Clubs City Collection or to book a reservation, please visit www.MarriottVacationClubs.com .

Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2023 and Reiterates Key Anticipated Near-Term Milestones

Retrieved on: 
Monday, August 14, 2023
Retina, Injection, Bevacizumab, Partnership, PIER, Anti-VEGF, PHSA, GlobalData, Special Protection Area, DME, Pharmacy, Marketing, AMD, AmerisourceBergen, Safety, Calendar, Clinical trial, Advanced Therapy Medicinal Product, Diabetic retinopathy, Intraocular pressure, Acquisition, Alliance Healthcare, Standard of care, Patient, Physician, Fujifilm Diosynth Biotechnologies, PDUFA, MAA, FDA, CHMP, Therapy, BLA, BRVO, JAMA, Syringe, Pharmaceutical industry, Medical device, EU

By meeting strict FDA requirements for an ophthalmic approved formulation of bevacizumab, we believe we can enhance the standard of care.

Key Points: 
  • By meeting strict FDA requirements for an ophthalmic approved formulation of bevacizumab, we believe we can enhance the standard of care.
  • This represents approximately 3.5 million injections of off-label, repackaged bevacizumab each year in the United States alone.
  • Globally, the nine major markets account for an estimated $13.1 billion market for anti-VEGF drugs to treat retina diseases.
  • In August 2022, Outlook Therapeutics submitted a PHSA 351(a) BLA for ONS-5010 as an original biologic application.

Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2023 and Provides Corporate Update

Retrieved on: 
Monday, May 15, 2023
Retina, Injection, Bevacizumab, Partnership, PIER, Anti-VEGF, PHSA, GlobalData, Special Protection Area, DME, Pharmacy, Marketing, AMD, AmerisourceBergen, Safety, Fiscal, Calendar, Clinical trial, Advanced Therapy Medicinal Product, Diabetic retinopathy, Intraocular pressure, Acquisition, Alliance Healthcare, Patient, Physician, Fujifilm Diosynth Biotechnologies, PDUFA, MAA, FDA, CHMP, Therapy, BLA, BRVO, Syringe, Pharmaceutical industry, Generic drug, EU

These initiatives are focused on positioning Outlook Therapeutics as an upcoming leader in the anti-VEGF space by meeting FDA requirements for an ophthalmic approval.

Key Points: 
  • These initiatives are focused on positioning Outlook Therapeutics as an upcoming leader in the anti-VEGF space by meeting FDA requirements for an ophthalmic approval.
  • The ONS-5010 Biologics License Application (BLA) was submitted and accepted for filing by the FDA as a 351(a) stand-alone BLA.
  • As Outlook Therapeutics moves toward a potential launch in the United States, AmerisourceBergen’s commercialization support will expand to include additional services.
  • Outlook Therapeutics also submitted a Marketing Authorization Application (MAA) in Europe, which was validated for review in December 2022.

FIVE LAST-MINUTE MEMORIAL DAY DESTINATIONS FOR A GETAWAY TO REMEMBER

Retrieved on: 
Thursday, May 11, 2023
Chairlift, Skiing, Arches National Park, Wi-Fi, Breckenridge Ski Resort, Club Wyndham South Pacific, Ginn Tribute Hosted by Annika, Bay, Marriott Vacation Club, PIER, Las Vegas Strip, Canyonlands National Park, ILG, Inc., Friends, Arapahoe Basin, Marriott Vacations Worldwide, Golf, Walking, Swimming, Memorial, Interval, Red Rocks Amphitheatre, WorldMark by Wyndham, Spring, Fisherman's Wharf, Main Street, ARDA, Tennis, White Cloud Peak 7, Brae, Sun, Summer Sun, Memorial Day, Family, Lake, Volleyball, UT, Fairfield Glade, Tennessee, Glade, Hilton Grand Vacations, Adventuredome, Westgate Las Vegas, Colorado Rockies, Ghirardelli Square, Snowflake, Hotel, Tourism, Sports equipment, Amusement park

WASHINGTON, May 11, 2023 /PRNewswire/ -- As Memorial Day approaches, vacation planning is top of mind for most travelers.

Key Points: 
  • WASHINGTON, May 11, 2023 /PRNewswire/ -- As Memorial Day approaches, vacation planning is top of mind for most travelers.
  • Our partners have an unbeatable portfolio of properties in coveted destinations across the globe that are sure to bring families and friends together for memorable experiences."
  • Travelers who visit during Memorial Day tend to have the mountain to themselves and don't have to worry about over-crowded restaurants.
  • Take advantage of the current Stay Longer rate to save more on a guest's next getaway of 3-nights or more.

Bell propels the growth of Canadian businesses with the Montréal accelerator Centech

Retrieved on: 
Thursday, November 24, 2022
Bell Let's Talk, Environment, Entrepreneurship, Partnership, Robotics, ESG, Internet, Engineering, Knowledge, Telecommunication, Vector Institute, Mental health, Ecosystem, Automation, Investment, Acceleration, Health, Science, Growth, MONTRAL, TS, Microsystems, Research, Medtech, Transport, AI, PIER, VR, Artificial intelligence, Communications satellite, Mobile phone, Enrique Dussel, CeNTech

Bell is the exclusive telecommunications partner of Centech, supporting emerging businesses with its 5G technology and solutions

Key Points: 
  • Bell is the exclusive telecommunications partner of Centech, supporting emerging businesses with its 5G technology and solutions
    MONTRAL, Nov. 23, 2022 /CNW Telbec/ - Bell today announced a three-year strategic relationship with Montral innovation centre, Centech.
  • As Centech's exclusive telecommunications provider, Bell will leverage its advanced network capabilities, 5G and AI management expertise to help emerging Canadian businesses drive innovation, growth and adoption of advanced technological solutions.
  • Centech's accelerator environment enables Bell to partner with entrepreneurs and start-ups, including Haply Robotics , a start-up that develops 3D haptic controllers.
  • We are proud to contribute to the success of local businesses with our world-class networks and the strength of Bell team members."

Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD

Retrieved on: 
Friday, October 28, 2022
Human, BRVO, Effectiveness, Clinical trial, Retina, Security (finance), Ranibizumab, U.S. Securities and Exchange Commission, Bevacizumab, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, VEGF, Safety, Nasdaq, CEO, Terminology, Retinal, BLA, Food, Endothelium, PDUFA, File, DME, Annual report, Patient, Biologics license application, Research, COVID-19, Risk, GLOBE, Therapy, FDA, Standard of care, AmerisourceBergen, Diosynth, PIER, AMD, Arm, Mab, KDR, Partnership, Pharmaceutical industry, Ophthalmology, Outlook

That product configuration does not meet the same standards we must achieve to earn FDA approval in ophthalmology.

Key Points: 
  • That product configuration does not meet the same standards we must achieve to earn FDA approval in ophthalmology.
  • If approved, ONS-5010 can replace the need to use unapproved repackaged oncologic IV bevacizumab from compounding pharmacies for the treatment of wet AMD.
  • The FDA accepted Outlook Therapeutics BLA submission for ONS-5010 to treat wet AMD with a PDUFA goal date of August 29, 2023.
  • The submission is supported by Outlook Therapeutics wet AMD clinical program, which consists of three clinical trials: NORSE ONE, NORSE TWO, and NORSE THREE.

Child Rescue Coalition Launches APOLLO, First-of-its-Kind System, Giving Academics Access to Live Data to Help Study the Behavior of Predators Involved in Online Child Sexual Exploitation

Retrieved on: 
Tuesday, October 11, 2022
Technology, Homeland Security, Congressional News, Views, Law Enforcement, Emergency Services, Public Policy, Government, Internet, Public Policy, Other Policy Issues, Public Safety, Anglia Ruskin University, Trust, ARU, Apollo, Minor, APOLLO, Arrest, OnlyFans, Organization, CSAM, National, Research, CRC, Multimedia, Partnership, Technology, Non-governmental organization, Sex, PIER, Behavior, US-China Strategic Engagement, Law enforcement, CEO, IP, Social media, Safety, Sexual abuse, Child, USD, Crime, Sex industry, Private investigator, Music, Metaverse

Child Rescue Coalition (CRC), a US-based non-profit, has announced a new initiative to improve the worldwide response to the threat of online child sexual abuse.

Key Points: 
  • Child Rescue Coalition (CRC), a US-based non-profit, has announced a new initiative to improve the worldwide response to the threat of online child sexual abuse.
  • For the first time, academics will be able to use data secured by CRC from online chat rooms, to analyze conversations between offenders with a sexual interest in children.
  • For the first time ever, were allowing academia to study online chat groups, where people with a sexual interest in children are meeting to discuss child sexual abuse and share child sexual abuse material.
  • Child Rescue Coalition (CRC), a south Florida-based nonprofit organization with global reach, has spent the past decade building the worlds most sophisticated technology to hunt child predators.

Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration

Retrieved on: 
Tuesday, August 30, 2022
COVID-19, Human, CEO, Safety, Research, U.S. Securities and Exchange Commission, CATT, GLOBE, Patient, Visual impairment, Inflammation, BLA, KDR, Retina, BRVO, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, VEGF, Food, Nasdaq, FDA, National Eye Institute, Terminology, Syringe, Security (finance), Therapy, Mab, Risk, Ranibizumab, Endothelium, AMD, Review, Marketing, Bevacizumab, Effectiveness, Physician, DME, Diosynth, Retinal, Biologics license application, National Eye, Clinical trial, Annual report, PIER, Pharmaceutical industry, Outlook, Agency, Ophthalmology

In anticipation of potential FDA marketing approval in 2023, Outlook Therapeutics has continued its commercial launch planning.

Key Points: 
  • In anticipation of potential FDA marketing approval in 2023, Outlook Therapeutics has continued its commercial launch planning.
  • These activities include establishing best-in-class partnerships with FUJIFILM Diosynth Biotechnologies for drug substance, and with drug product manufacturer Ajinomoto Bio-pharma Services for finished drug product.
  • NORSE ONE was a clinical experience trial involving 61 wet AMD participants at nine trial sites in Australia.
  • Outlook Therapeutics has submitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ONS-5010 to treat wet AMD.

PIER 39 ANNOUNCES NEW PRESIDENT AND CEO WILL TAKE HELM IN 2023

Retrieved on: 
Wednesday, June 29, 2022
Travel, SFSU, Blue & Gold Fleet, CEO, Hotel manager, Port, LLP, Accounting, Business administration, Berkeley, GLOBE, San Francisco State University, Inland, Intelligence, Growth, Commerce, Association, CPA, Restaurant, CFO, MBA, PIER, KPMG, BA, University, Controller, Chamber of commerce, Gentner, CA, Risk management, Executive, Blue, Java transaction service, Professional, Information technology, Management, Amusement park, Port of San Francisco

Effective on December 31, 2022, PIER 39 President and Chief Executive Officer, Taylor Safford, will be retiring.

Key Points: 
  • Effective on December 31, 2022, PIER 39 President and Chief Executive Officer, Taylor Safford, will be retiring.
  • Gentner will oversee all aspects of the PIER 39 Companies, including ferry and tour boat operator, Blue & Gold Fleet.
  • The San Francisco Travel Association conducts a Visitor Profile Study every 4 years and PIER 39 has held the top spot since 2010.
  • PIER 39 also includes a five-acre waterfront park and 300-berth marina, home to the world-famous California Sea Lions.

Liqid and PIER Group Announce Agreement to Bring Composable Disaggregated Infrastructure Solutions to Research and Education Communities

Retrieved on: 
Thursday, April 14, 2022
Data Management, Security, Technology, Other Technology, Software, Internet, Hardware, FPGA, Scientific method, Solid-state drive, Twitter, Libraries and the US National Research and Education Network, Software, Research, NVM Express, R, CDI, Time Machine, Organization, Education, Machine learning, LinkedIn, Efficiency, Integration, Technology, GPU, Solution, CPU, Workload, HPC, Graphics processing unit, PIER, Intelligence, SLURM, Â, Industry, University, Field-programmable gate array, API, NVME, Channel, Video game console

Liqid , the worlds leading software company delivering data center composability, today announced a new agreement with PIER Group to sell Liqids line of composable disaggregated infrastructure (CDI) solutions and services to research and education (R&E) customers.

Key Points: 
  • Liqid , the worlds leading software company delivering data center composability, today announced a new agreement with PIER Group to sell Liqids line of composable disaggregated infrastructure (CDI) solutions and services to research and education (R&E) customers.
  • In order to remain globally competitive, academic institutions need dynamic, performance-oriented infrastructure that can adapt to the changing demands of modern computing, said Chad Williams, President, PIER Group.
  • PIER Groups experience and expertise within the research and education community makes them an outstanding representative for Liqids technology, said Nader Soudah, Vice President, Channel, Liqid.
  • PIER Group formed in early 2018, as the result of a groups passion for the Research and Education industry.